Theolytics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Science Park Edmund Halley Oxford Rd, Ox...Website
www.theolytics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Theolytics
Theolytics is a biotech company based in England that focuses on developing innovative oncolytic immunotherapy to combat solid tumors, particularly ovarian cancer. Their ADENOVO discovery platform utilizes viruses to create targeted therapies aimed at transforming patients' lives. The company combines expertise in virology, cancer biology, and immunology, partnering with top-tier investors and biopharmaceutical firms. Theolytics is committed to ensuring that everyone has access to groundbreaking therapies that promise lasting cures.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Theolytics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Theolytics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Theolytics
Check out if Theolytics is spiking on competitors!
Check if Theolytics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Theolytics has new funding data
Theolytics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Theolytics had a recent Job posting/layoffs
Product Launch: Get notified when Theolytics launches new products
Recommended Actions
Find VP level buyers at Theolytics
Find more new buyers
Compare Similar Companies to Theolytics
Compare insights from companies similar to Theolytics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Theolytics
<$5M
11-50
Private
$6.8M
2017
N/A
Company Profile Activity
Activity Insights
Theolytics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Theolytics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Theolytics.
Theolytics financials insights
Gather financial insights about Theolytics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$6.8M
Theolytics Tech Stack
A closer look at the technologies used by Theolytics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Board of Directors
Left Company
Executive Move
Board of Directors
Theolytics News & Media
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
Oxford, UK, April 28, 2026 — Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO-260 for the treatment of women with Platinum-Resistant Ovarian Cancer (PROC) (NCT07211659).Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer
Oxford UK, March 4, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has been awarded, pending final negotiation, €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme. Horizon Europe 2025 is supporting high-impact clinical-stage projects aimed at improving patient outcomes and strengthening Europe’s scientific leadership. The grant to Theolytics willTheolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025
Oxford UK, October 13, 2025. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, will present a Trials in Progress Poster at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany from October 17-21. Dr Margaret Duffy, CSO and Dr Matilde Saggese, CMO will be attending and will showcase the OCTOPOD-IV Phase I/IIa clinical trial of THEO-260, a novel oncolytic immunotherapy, given by intravenous delivery in patTheolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
Oxford UK, October 7, 2025. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO). Dr Saggese will lead clinical development and regulatory activities for Theolytics, including for its lead asset THEO-260, which is being investigated in UK and US trials evaluating two different routes of administration (IV and IP, respectively) in patients with platinum-resist
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Theolytics
Sign Up For FreeTo access detailed company insights
Theolytics is a biotech company based in England that focuses on developing innovative oncolytic immunotherapy to combat solid tumors, particularly ovarian cancer. Their ADENOVO discovery platform utilizes viruses to create targeted therapies aimed at transforming patients' lives. The company combines expertise in virology, cancer biology, and immu... Read More
